Health |ImmunityBio
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
October 21, 2026 · 7:30 AM · CULVER CITY, Calif.
ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced completion of the database lock for Cohort A of QUILT-2.005 (NCT02138734), its randomized, controlled, registrational trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) versus BCG alone in patients with BCG-naïve NMIBC. The chemotherapy-free combination is delivered directly into the bladder. The database lock follows the...
- PublishedOctober 21, 2026 · 7:30 AM
- LocationCULVER CITY, Calif.
- IndustryHealth
- LanguageEN
Published by Business Wire. Read the original announcement for the full release.
Read the full announcement →